RBC Capital Maintains Outperform on Amgen, Raises Price Target to $329
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza maintains an Outperform rating on Amgen (NASDAQ:AMGN) and raises the price target from $303 to $329.
February 07, 2024 | 4:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital analyst Gregory Renza maintains an Outperform rating on Amgen and raises the price target from $303 to $329.
The increase in price target by RBC Capital suggests a positive outlook on Amgen's stock, potentially leading to an increase in investor confidence and a short-term rise in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100